PMID- 18787660
OWN - NLM
STAT- MEDLINE
DCOM- 20090317
LR  - 20211028
IS  - 1488-2434 (Electronic)
IS  - 1180-4882 (Print)
IS  - 1180-4882 (Linking)
VI  - 33
IP  - 5
DP  - 2008 Sep
TI  - BDNF protein levels are decreased in transformed lymphoblasts from 
      lithium-responsive patients with bipolar disorder.
PG  - 449-53
AB  - OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is a key factor in 
      neuroplasticity and has been implicated in the affective disorders; studies have 
      demonstrated elevated BDNF in patients taking lithium and other mood stabilizers. 
      The objective of our study was to analyze BDNF in lithium-responsive patients 
      with bipolar disorder (BD) to further understand the role of BDNF in the 
      pathophysiology of BD. METHODS: Using enzyme-linked immunosorbent assay, we 
      measured transformed B lymphocytes for BDNF protein. RESULTS: BDNF levels were 
      36% lower in lymphoblasts from patients with BD (n = 12), compared with matched 
      control participants (n = 13), and 55% lower when compared with their unaffected 
      relatives (n = 14). Lithium significantly decreased BDNF levels in patients with 
      BD and healthy control participants, although BDNF levels remained lower (33%) in 
      the BD group posttreatment. CONCLUSION: Decreased BDNF may constitute part of the 
      pathophysiologic process of BD in a lithium-responsive subgroup of individuals 
      with this disease. A compensatory mechanism protecting the genetically 
      predisposed unaffected relatives from phenotypic expression of BD is suggested.
FAU - Tseng, Michael
AU  - Tseng M
AD  - Department of Psychiatry, Centre for Addiction and Mental Health, University of 
      Toronto, Toronto, Ontario, Canda.
FAU - Alda, Martin
AU  - Alda M
FAU - Xu, Li
AU  - Xu L
FAU - Sun, Xiujun
AU  - Sun X
FAU - Wang, Jun-Feng
AU  - Wang JF
FAU - Grof, Paul
AU  - Grof P
FAU - Turecki, Gustavo
AU  - Turecki G
FAU - Rouleau, Guy
AU  - Rouleau G
FAU - Young, L Trevor
AU  - Young LT
LA  - eng
GR  - 64410/CAPMC/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Psychiatry Neurosci
JT  - Journal of psychiatry & neuroscience : JPN
JID - 9107859
RN  - 0 (Antimanic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 2BMD2GNA4V (Lithium Carbonate)
SB  - IM
MH  - Adult
MH  - Antimanic Agents/*therapeutic use
MH  - *Bipolar Disorder/blood/drug therapy/physiopathology
MH  - Brain-Derived Neurotrophic Factor/*blood/*genetics
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Lithium Carbonate/*therapeutic use
MH  - Lymphocyte Activation/*physiology
MH  - Male
MH  - Middle Aged
MH  - Young Adult
PMC - PMC2527719
OTO - NOTNLM
OT  - bipolar disorder
OT  - brain-derived neurotrophic factor
OT  - enzyme-linked immunosorbent assay
OT  - lithium
EDAT- 2008/09/13 09:00
MHDA- 2009/03/18 09:00
PMCR- 2008/09/01
CRDT- 2008/09/13 09:00
PHST- 2008/09/13 09:00 [pubmed]
PHST- 2009/03/18 09:00 [medline]
PHST- 2008/09/13 09:00 [entrez]
PHST- 2008/09/01 00:00 [pmc-release]
AID - 0001585-200809000-00008 [pii]
PST - ppublish
SO  - J Psychiatry Neurosci. 2008 Sep;33(5):449-53.